These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 7522527

  • 1. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
    Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M.
    Ann Oncol; 1994 Jul; 5(6):521-6. PubMed ID: 7522527
    [Abstract] [Full Text] [Related]

  • 2. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck.
    Clavel M, Cognetti F, Dodion P, Wildiers J, Rosso R, Rossi A, Gignoux B, Van Rymenant M, Cortes-Funes H, Dalesio O.
    Cancer; 1987 Sep 15; 60(6):1173-7. PubMed ID: 2441836
    [Abstract] [Full Text] [Related]

  • 3. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    Amrein PC, Fabian RL.
    Laryngoscope; 1992 Aug 15; 102(8):901-6. PubMed ID: 1379664
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G, Armand JP, Tellez-Bernal E, Domenge C, Belehradek M, De Vathaire F, Wibault P, Richard JM, Cvitkovic E.
    Laryngoscope; 1991 May 15; 101(5):494-501. PubMed ID: 1709437
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alternating regimens in recurrent and metastatic squamous cell carcinoma of the head and neck.
    Cognetti F, Molinari A, Carlini P, Frassineti GL, Pinnarò P, Marangolo M.
    Oncology; 1987 May 15; 44(5):270-2. PubMed ID: 2444912
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA, SPECTRUM investigators.
    Lancet Oncol; 2013 Jul 15; 14(8):697-710. PubMed ID: 23746666
    [Abstract] [Full Text] [Related]

  • 13. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR.
    Ann Oncol; 1999 Jan 15; 10(1):119-22. PubMed ID: 10076732
    [Abstract] [Full Text] [Related]

  • 14. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.
    J Clin Oncol; 2005 Dec 01; 23(34):8636-45. PubMed ID: 16275937
    [Abstract] [Full Text] [Related]

  • 15. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
    Mutlu H, Salim DK, Gündüz Ş, Eryılmaz MK, Musri FY, Coşkun HŞ.
    J Cancer Res Ther; 2017 Dec 01; 13(3):510-513. PubMed ID: 28862218
    [Abstract] [Full Text] [Related]

  • 16. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
    Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L.
    J Clin Oncol; 1992 Feb 01; 10(2):257-63. PubMed ID: 1732427
    [Abstract] [Full Text] [Related]

  • 17. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
    Iop A, Cartei G, Isaia A.
    Ann Oncol; 1998 Feb 01; 9(2):225-7. PubMed ID: 9553671
    [Abstract] [Full Text] [Related]

  • 18. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer.
    Vogl SE, Schoenfeld DA, Kaplan BH, Lerner HJ, Engstrom PF, Horton J.
    Cancer; 1985 Aug 01; 56(3):432-42. PubMed ID: 2408735
    [Abstract] [Full Text] [Related]

  • 19. Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
    Amrein PC, Weitzman SA.
    J Clin Oncol; 1985 Dec 01; 3(12):1632-9. PubMed ID: 2415693
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.
    Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Earley CL, Winn RJ, Brooks J, Baez L, Hong WK.
    Ann Oncol; 1995 Jan 01; 6(1):83-5. PubMed ID: 7536031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.